Raymond James Financial Inc. Sells 1,132 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Raymond James Financial Inc. reduced its stake in Thermo Fisher Scientific Inc. by 0.2%, possessing 725,280 shares valued at approximately $360.9 million after selling 1,132 shares.
• Several institutional investors significantly increased their holdings in Thermo Fisher, with GAMMA Investing LLC boosting its stake by over 60,000% during the first quarter.
• Thermo Fisher's stock showed a growth of 1.0%, with an earnings report that exceeded analysts' expectations, reporting $5.36 EPS for the quarter and revenue up 2.9% year-over-year.

Raymond James Financial Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.2% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 725,280 shares of the medical research company's stock after selling 1,132 shares during the quarter. Raymond James Financial Inc. owned 0.19% of Thermo Fisher Scientific worth $360,898,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares in the last quarter. Capital World Investors grew its position in shares of Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after buying an additional 104,343 shares in the last quarter. Northern Trust Corp raised its stake in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after purchasing an additional 455,004 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after acquiring an additional 1,433,444 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.7%

Shares of NYSE:TMO traded down $3.4740 during midday trading on Wednesday, reaching $494.8160. The company had a trading volume of 2,351,499 shares, compared to its average volume of 2,495,940. The company has a fifty day simple moving average of $438.09 and a two-hundred day simple moving average of $458.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $186.85 billion, a price-to-earnings ratio of 28.62, a price-to-earnings-growth ratio of 2.60 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm posted $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Barclays upped their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 8,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $52,340,824.30. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,400 shares of company stock valued at $8,345,792. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.